AmideBio
Boulder, US · Colorado LLC
AmideBio uses in-silico design and proprietary peptide synthesis to develop preclinical peptide drug candidates for metabolic disease. It also offers custom peptide synthesis services and a catalog of high-purity peptides for customers.
BiotechDeep Tech
Founders & leadership
DB
David BarkerDirector
VP
Vincent P. MihalikDirector
MH
Michael H.B. StowellExecutive Officer, Director
RC
Ruel C. MercureDirector
MP
Mikhail PlamExecutive Officer, Director
NU
Niles UtlautDirector
DB
David BrunelDirector
GA
Gregory AbbottDirector
Reported raises · per SEC filings
Form D private placements▶$763.5KraisedNov 2017 · 9 investors · BiotechnologyRule 506(b)
▶$763.5KraisedNov 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ruel C. MercureDirector
- David BrunelDirector
- Niles UtlautDirector
- Gregory AbbottDirector
- David BarkerDirector
- Michael H.B. StowellExecutive Officer, Director
- Mikhail PlamExecutive Officer, Director
- Vincent P. MihalikDirector
- Offering amount
- $763.5K
- Amount sold
- $763.5K
- First sale
- Oct 2017
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$396KraisedApr 2017 · 9 investors · BiotechnologyRule 506(b)
▶$396KraisedApr 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BarkerDirector
- Michael H.B. StowellExecutive Officer, Director
- Mikhail PlamExecutive Officer, Director
- Ruel C. MercureDirector
- Gregory AbbottDirector
- Vincent P. MihalikDirector
- David BrunelDirector
- Niles UtlautDirector
- Offering amount
- $768K
- Amount sold
- $396K
- First sale
- Apr 2016
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
▶$279.3KraisedJan 2015 · 5 investors · BiotechnologyRule 506(b)
▶$279.3KraisedJan 2015 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BarkerDirector
- Vincent P. MihalikDirector
- Michael H.B. StowellExecutive Officer, Director
- Ruel C. MercureDirector
- Mikhail PlamExecutive Officer, Director
- Niles UtlautDirector
- David BrunelDirector
- Gregory AbbottDirector
- Offering amount
- $1.1M
- Amount sold
- $279.3K
- First sale
- Dec 2014
- Incorporated
- Limited Liability Company, Colorado
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $338.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.